Gold prices just lower; monthly gains on track
Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics (NASDAQ:ELVN), sold 1,000 shares of common stock on July 10, 2025, for a total of $22,655. The sales were executed in multiple trades at prices ranging from $22.59 to $22.72. The stock, currently trading at $23, has shown strong momentum with a 14.6% gain in the past week. According to InvestingPro, analysts have set price targets ranging from $33 to $52 for the $1.36 billion market cap company.
According to a Form 4 filing with the Securities and Exchange Commission, Hohl also exercised options to acquire 1,000 shares of Enliven Therapeutics common stock at an exercise price of $2.48, for a total value of $2480.
Following the transactions, Hohl directly owns 23,000 shares of Enliven Therapeutics.
The option exercise and sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
In other recent news, Enliven Therapeutics has been actively engaging in several developments. The company announced a $200 million public offering, pricing 8,394,737 shares of common stock at $19.66 per share, with additional pre-funded warrants available for purchase. This offering, managed by Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho (NYSE:MFG), is expected to close around mid-June 2025. In clinical advancements, H.C. Wainwright raised its price target for Enliven Therapeutics to $48 from $40, following promising Phase 1a/1b trial results for its lead drug candidate, ELVN-001, in chronic myeloid leukemia (CML) patients. The trial showed a significant major molecular response rate, especially in patients resistant to previous treatments. Meanwhile, TD Cowen reiterated its buy rating, emphasizing the potential of ELVN-001 to become a standard therapy in the CML market, projecting peak sales of $3 billion. Additionally, Goldman Sachs initiated coverage with a buy rating and a $37 price target, citing favorable comparisons with existing treatments and a well-tolerated safety profile for ELVN-001. These developments underscore Enliven Therapeutics’ strategic efforts in advancing its clinical pipeline and securing financial resources.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.